Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP

Adagene Inc. ADAG

8 fiscal years on record · USD · FY2025 reported · SEC filings only
$7.7M
▲ 7332.8% YoY
$-17.6M
$-15.7M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 7.7M
Revenue, FY2025 · full 8-year series below
Revenue $M Net income $M
FY2025 · Revenue 7.7 · Net income -17.6
10M20M-30M-60M
2018202120242025
Compound annual growth
−6.2%
+61.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +61.4% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2023 · Operating -131.0% · Net -104.6%
-2000%-4000%-6000%
201820212025
ROE
FY2025 · ROE -41.0%
-20%-40%-60%
201820212025
Three returns, three denominators.

Each USD of equity lost 41 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -15.7
-20M-40M
201820212025
Net buybacks $M Dividends $M
FY2022 · Dividends · · Net buybacks 3.7
2M3M
20212022

Total assetsUSD 78.3M
EquityUSD 35.3M
CashUSD 74.5M
Gross debtUSD 1.8M
Net debtUSD -72.7M
Current ratio3.07×

The company holds more cash than debt.

The 8-year record

8 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ADAG, 8-year financial record
Metric 20252024202320222021202020192018
Revenue $B0.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.1−0.1−0.0−0.0−0.0
Income tax $B−0.0−0.00.00.00.0◌◌◌
Net income $B−0.0−0.0−0.0−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.30−0.59−0.35−1.48−1.46−2.67−1.10−0.94
Dividend / sh $◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————
ROE %−41.0−55.2−24.7−66.7————
Shares out B0.060.060.060.050.050.020.02◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 30 reconciliationsAUDITED

Reconciled in 8 of the 8 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 11 checks were skipped: EPS is not tagged before 2018.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2018

Share this section

Download image